MGuard™ Prime Stent System Clinical Trial in Patients With Acute ST Elevation Myocardial Infarction (MASTER-II)

This study has suspended participant recruitment.
(Voluntary field action)
Sponsor:
Information provided by (Responsible Party):
InspireMD
ClinicalTrials.gov Identifier:
NCT01869738
First received: May 28, 2013
Last updated: May 5, 2014
Last verified: May 2014
  Purpose

To evaluate the safety and efficacy of the MGuard™ Prime stent in the treatment of blocked arteries in coronary arteries in patients undergoing a stenting procedure due to having a heart attack. The MGuard Prime stent wil be compared to other FDA approved bare-metal (BMS) or drug-eluting (DES) coronary stents. The hypotheses are that (1) the MGuard Prime stent will achieve a higher rate of complete ST-segment resolution as seen on the post-procedure ECG as compared to the comparator stent, and will have a similar effect on the rate of all-cause death or recurrent target vessel myocardial infarction at 365 days post-procedure.


Condition Intervention
ST Elevation Myocardial Infarction
Device: MGuard Prime
Device: Control (BMS/DES)

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Subject)
Primary Purpose: Treatment
Official Title: MGuard™ Prime Stent System Clinical Trial in Patients With Acute ST Elevation Myocardial Infarction

Resource links provided by NLM:


Further study details as provided by InspireMD:

Primary Outcome Measures:
  • rate of complete ST-segment resolution within 60-90 minutes [ Time Frame: 60-90 minutes post-procedure ] [ Designated as safety issue: No ]
  • The primary safety endpoint is a composite of all-cause death or recurrent target vessel myocardial infarction (TV re-MI) at 365 days post-procedure, powered to demonstrate non-inferiority of the MGuard™ Prime Stent compared to the control arm. [ Time Frame: 365 days post-procedure ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Infarct size assessed by cardiac magnetic resonance imaging (MRI) [ Time Frame: 5 days post-procedure ] [ Designated as safety issue: No ]
  • In-stent late lumen loss (LLL) [ Time Frame: 13 months post-procedure ] [ Designated as safety issue: No ]

Estimated Enrollment: 1114
Study Start Date: June 2013
Estimated Study Completion Date: June 2016
Estimated Primary Completion Date: June 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: MGuard Prime
MGuard Prime stent
Device: MGuard Prime
Active Comparator: Control
Includes FDA approved bare metal or drug eluting stents, including ENDEAVOR, TAXUS Liberte, XIENCE Prime, PROMUS Element, ION, RESOLUTE, Driver, Vision, VeriFlex and Integrity.
Device: Control (BMS/DES)

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subject is more than 18 years of age
  • Subject is experiencing clinical symptoms consistent with acute myocardial infarction (AMI) of more than 30 minutes and less than 12 hours in duration.
  • ST elevation more than 2 mm per lead in more than 2 contiguous leads is present in one ECG prior to consent.
  • Subject agrees to all required follow-up procedures and visits.
  • Subject or legal representative provides written, informed consent.
  • The target lesion is a de novo lesion in a native coronary artery.
  • Based on coronary anatomy, PCI is indicated for the culprit lesion with anticipated use of stenting.
  • The reference vessel diameter (RVD) of the infarct lesion is 2.75 to 4.0 mm by visual assessment, assessed either at baseline (if direct stenting is planned), or after pre-dilatation or thrombus aspiration (if direct stenting is not planned).
  • The entire lesion length requiring treatment is less than 24 mm (able to be covered by a single study stent), assessed either at baseline (if direct stenting is planned), or after pre-dilatation or thrombus aspiration (if direct stenting is not planned)
  • TIMI flow of 2/3 is present prior to randomization (in case of baseline TIMI flow 0/1, blood flow must be restored).

Exclusion Criteria:

  • Left bundle branch block (LBBB), paced rhythm, or other ECG abnormality interfering with assessment of ST-segment.
  • Currently enrolled in another investigational device or drug trial that has not completed the primary endpoint or that clinically interferes with the current study endpoints.
  • A previous coronary interventional procedure of any kind within 30 days prior to the procedure.
  • Female patients of childbearing potential.
  • Subject undergoing cardiopulmonary resuscitation (patients in whom cardiopulmonary resuscitation was successfully performed and in whom normal mental status was achieved, may be enrolled).
  • Cardiogenic shock (SBP less than 80 mmHg for more than other hemodynamic support device for hypotension).
  • The subject requires a staged procedure of the target vessel (including branches) within 12 months or of any non-target vessel within 7 days post-procedure.
  • The target lesion requires treatment with a device other than PTCA prior to stent placement (such as, but not limited to excimer laser, rotational atherectomy, etc.). Manual thrombus aspiration may be used per operator discretion, but rheolytic thrombectomy is only permitted for procedural complications after randomization.
  • Prior administration of thrombolytic therapy for the current admission
  • Co-morbid condition(s) that could limit the subject's ability to participate in the trial or to comply with follow-up requirements, or impact the scientific integrity of the trial.
  • Concurrent medical condition with a life expectancy of less than 12 months.
  • History of cerebrovascular accident or transient ischemic attack within the last 6 months, or any permanent neurologic deficit
  • Prior intracranial bleed at any time, or known intracranial pathology (e.g. tumor, arteriovenous malformation, or aneurysm).
  • Active or recent site of major bleeding within 6 months.
  • History of bleeding diathesis or coagulopathy or inability to accept blood transfusions.
  • Known hypersensitivity or contraindication to either i) aspirin, or heparin and bivalirudin; or ii) clopidogrel , ticlopidine, prasugrel and ticagrelor; or iii) cobalt or nickel; or iv) contrast media, which cannot be adequately pre-medicated (prior anaphylaxis, however, is an absolute contraindication to enrollment).
  • Known serum creatinine level more than 2.5 mg/dl, hemoglobin less than 10 g/dL or platelet count less than 150,000 for the present admission or within 7 days prior to index procedure, if available.
  • Surgery planned or any other reason necessitating discontinuation of dual anti-platelet therapy (aspirin and an ADP antagonist) within 12 months
  • Aortic dissection or mechanical complication of STEMI
  • Unprotected left main stenosis more than 50%.
  • Multi-vessel intervention required during the index procedure.
  • Excessive tortuosity, calcification or diffuse distal disease
  • A non-infarct lesion with stenosis more than 50% is present in the target vessel
  • Target lesion is a bifurcation with a side branch more than 2.0 mm in diameter.
  • Target lesion at the site of or within a vessel with a previously implanted stent
  • Target lesion is within a bypass graft conduit, or can only be reached by passing the study stent through a bypass graft conduit
  • In the Investigator's opinion the lesion/vessel is unsuitable for treatment with the study stent for any reason.
  • The lesion requires use of atherectomy, thrombectomy (not including manual thrombus aspiration catheters), laser devices, or proximal or distal embolic protection devices prior to randomization.
  • Aortic dissection or mechanical complication of STEMI
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01869738

  Hide Study Locations
Locations
United States, Connecticut
Yale University School of Medicine
New Haven, Connecticut, United States, 06510
United States, Florida
Pepin Heart Hospital
Tampa, Florida, United States, 33613
United States, Illinois
Alexian Brothers Medical Center
Elk Grove Village, Illinois, United States, 60007
United States, Indiana
St. Vincent Medical Group
Indianapolis, Indiana, United States, 46290
United States, Maryland
MedStar Union Memorial Hospital
Baltimore, Maryland, United States, 21218
MedStar Southern Maryland Hospital Center
Clinton, Maryland, United States, 20735
United States, Michigan
Sparrow Clinical Research Institute
Lansing, Michigan, United States, 48910
Beaumont Hospital
Royal Oak, Michigan, United States, 48073
United States, Mississippi
Cardiology Associates of North Mississippi
Oxford, Mississippi, United States, 38655
United States, New Jersey
Valley Hospital
Ridgewood, New Jersey, United States, 07450
United States, New York
Columbia University Medical Center
New York, New York, United States, 10027
United States, North Carolina
Asheville Cardiology Associates
Asheville, North Carolina, United States, 28803
United States, Ohio
University Hospitals Case Medical Center
Cleveland, Ohio, United States, 44106
Elyria Memorial Hospital
Oberlin, Ohio, United States, 44074
Northwest Ohio Cardiology
Toledo, Ohio, United States, 43615
United States, Pennsylvania
Holy Spirit Hospital
Camp Hill, Pennsylvania, United States, 17011
Geisinger Clinic Cardiology
Danville, Pennsylvania, United States, 17822
United States, Rhode Island
Miriam Hospital
Providence, Rhode Island, United States, 02906
United States, Virginia
University of Virginia Health System
Charlottesville, Virginia, United States, 22903
Winchester Medical Center
Winchester, Virginia, United States, 22604
Belgium
ZNA Antwerpem
Antwerp, Belgium
Czech Republic
University hospital
Hradec Kralove, Czech Republic
Na Homolce Hospital
Prague, Czech Republic
Estonia
North-Estonia Regional Hospital
Tallinn, Estonia, 13419
Finland
Helsinki University Hospital
Helsinki, Finland
France
Hopital Henri Mondor
Créteil, France
Hopital Louis Pradel
Lyon, France
Institut Jacques Cartier
Massy, France
Hôpitaux GHI Le Raincy - Montfermeil
Montfermeil, France
Hôptal Européen Georges Pompidou
Paris, France
Germany
Charité Universitätsklinikum Berlin Campus Virchow
Berlin, Germany, 10117
Charité Universitätsklinikum Berlin Campus Benjamin Franklin
Berlin, Germany, 10117
Stadtische Kliniken München
Munich, Germany, 81925
Krankenhaus der Barmherzigen Brüder
Trier, Germany, 54292
Universitat Ulm
Ulm, Germany, 89081
Israel
Rabin Medical Center
Petach Tikva, Israel, 49100
Netherlands
Onze Lieve Vrouwe Gasthuis
Amsterdam, AC, Netherlands, 1091
Academic Medical Center
Amsterdam, Netherlands
VU University Medical Center
Amsterdam, Netherlands, 1081
Albert Schweitzerziekenhuis
Dordrecht, Netherlands, 3318
Poland
Malopolskie Centrum Sercowo-Naczyniowe
Chrzanow, Poland
Polsko-Amerykańskie Kliniki Serca
Dąbrowa Górnicza, Poland
Górnośląskie Centrum Medyczne
Katowice, Poland, 40-635
John Paul II Hospital
Krakow, Poland
Szpital Uniwersyteckiw Krakowie
Krakow, Poland, 31-501
Krakowskie Centrum Kardiologii Inwazyjnej
Krakow, Poland, 30-693
Klinika Kardiologii i Angiologii Interwencyjnej
Warsaw, Poland, 04 - 628
Katedra i Klinika Kardiologii Uniwersytetu Medycznego w Łodzi
Łódź, Poland
Spain
Hospital Clinic, University of Barcelona
Barcelona, Spain, 08036
Bellvitge University Hospital
Barcelona, Spain, 08907
Hospital Universitario Madrid Montepríncipe
Madrid, Spain, 28660
United Kingdom
Bristol Heart Institute
Bristol, United Kingdom
University Hospital of Wales
Cardiff, United Kingdom
Golden Jubilee National Hospital
Glasgow, United Kingdom
Leeds General Infirmary
Leeds, United Kingdom
University Hospitals Southampton NHS Foundation Trust
Southampton, United Kingdom
Sponsors and Collaborators
InspireMD
  More Information

No publications provided

Responsible Party: InspireMD
ClinicalTrials.gov Identifier: NCT01869738     History of Changes
Other Study ID Numbers: IMD-10
Study First Received: May 28, 2013
Last Updated: May 5, 2014
Health Authority: United States: Food and Drug Administration
Germany: Federal Institute for Drugs and Medical Devices
Belgium: Ethics Committee
France: Agence Nationale de Sécurité du Médicament et des produits de santé
Netherlands: Medical Ethics Review Committee (METC)
United Kingdom: National Institute for Health Research

Keywords provided by InspireMD:
heart attack

Additional relevant MeSH terms:
Infarction
Myocardial Infarction
Ischemia
Pathologic Processes
Necrosis
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Vascular Diseases

ClinicalTrials.gov processed this record on September 18, 2014